![Israel drama and good news for the F-35: Paris Air Show Day 1 [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/IMG_1805-scaled-e1750092662883.jpg?#)
![[Updated] Sudden Deployment of Dozens of U.S. Air Force Tankers Raises Questions](https://theaviationist.com/wp-content/uploads/2025/03/Stratotanker100Years_2-e1750080240327.jpg)
STAT+: After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry
Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other parents still push for the therapy.
The death of a second teenage boy from liver failure caused by a gene therapy from Sarepta Therapeutics has left the Duchenne muscular dystrophy community angry, fearful and divided over whether to maintain hope in the therapy.
Kameron Lawson learned about the boy’s death from a phone call from his son’s neurologist on Sunday morning. His own 10-year-old son, Konner, received the treatment, called Elevidys, in early April and began experiencing signs of liver failure six weeks later. He has been hospitalized multiple times with liver problems since then, and his prognosis remains uncertain.
Hearing that a second boy with Duchenne had died from liver failure after receiving Elevidys was a shock, said Kameron Lawson, speaking to STAT on Sunday night from their home in Stockton, Calif. “This kid died from the same thing we’re trying to fight off right now,” said Lawson. “It really sent it home for us where we’re at right now.”
